SCANDION ONCOLOGY AS has a total of 13 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2015. It filed its patents most often in EPO (European Patent Office), Australia and Brazil. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and measurement are ALTAVANT SCIENCES GMBH, KOTOSUGI INC and SIDEM PHARMA.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 3 | |
#2 | Australia | 2 | |
#3 | Brazil | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Canada | 1 | |
#6 | Hungary | 1 | |
#7 | Serbia | 1 | |
#8 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds | |
#4 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Stenvang Jan | 7 |
#2 | Thougaard Annemette | 6 |
#3 | Lichtenberg Jens | 6 |
#4 | Christophersen Palle | 6 |
#5 | Brünner Nils Aage | 4 |
#6 | Rump Steffen | 2 |
#7 | Brünner Nils | 2 |
#8 | Weigt Henning | 2 |
#9 | Bruenner Nils | 1 |
#10 | Steffen Rump | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020079051A1 | Compounds for treatment of microbial infection | |
WO2020049139A1 | Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1 | |
EP3064207A1 | 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments |